PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Proteomics Clin Appl. Author manuscript; available in PMC 2010 August 26.
Published in final edited form as:
PMCID: PMC2808139
NIHMSID: NIHMS159783

Sources of Urinary Proteins and their Analysis by Urinary Proteomics for the Detection of Biomarkers of Disease

Abstract

Renal disorders account for a substantial fraction of the budget for health care in many countries. Proteinuria is a frequent manifestation in afflicted patients, but the origin of the proteins varies based on the nature of the disorder. The emerging field of urinary proteomics has the potential to replace kidney biopsy as the diagnostic procedure of choice for patients with some glomerular forms of renal disease. To fully realize this potential, it is vital to understand the basis for the urinary excretion of protein in physiological and pathological conditions. In this review, we discuss the structure of the nephron, the functional unit of the kidney, and the process by which proteins/peptides enter the urine. We discuss several aspects of proteinuria that impact the proteomic analysis of urine of patients with renal diseases.

Keywords: Glomerular Filtration, Nephron, Proteinuria, Proteomics, Renal Tubule

Twenty-four hundred years ago, Hippocrates noted the association between bubbles on the surface of voided urine and kidney disease. This foamy appearance is due to proteinuria, an abnormality oftentimes discovered during routine evaluations in the primary-care setting. The clinical significance of this finding varies widely. Some individuals will be shown to have a benign cause, such as fever, intense activity, exercise, orthostatic proteinuria, or acute illness. Alternatively, serious conditions include a host of ailments intrinsic to the kidney (glomerulonephritis, tubular disorders, interstitial renal disease, and hypertensive renal damage) and various extra-renal disorders (plasma cell dyscrasia, inflammation of the urinary tract, and uroepithelial tumors). To ensure an accurate and timely diagnosis, a knowledgeable approach to the evaluation of proteinuria is critical.

Structure of the nephron

The functional unit of the kidney is the nephron and each normal human kidney contains about 1 × 106 such units. Its essential components are the glomerulus and the tubule (Figure 1). The glomerulus is the site of formation of the primary urine. It is composed of a capillary network lined by a thin layer of endothelial cells separated from overlying epithelial cells (podocytes) by a basement membrane. Bowman’s space is covered by epithelial cells and is the collection site for the primary urine. Upon exiting this space, the urine enters the tubule where its composition is drastically altered before leaving the kidney. The tubule can be divided into several functional segments that differ in their capacities to reabsorb solutes, proteins, and water and secrete various compounds [1]. These structures are interspaced in the interstitium with its small vessels and extracellular matrix.

Figure 1
Kidney and its structural and functional components. Each human kidney (left top) contains ~1,000,000 functional units or nephrons (middle, top) that span the two regions of the kidney: cortex and medulla. Each nephron is composed of a filtration structure ...

The glomerular capillary endothelial cells have many fenestrae with diameters ~60–90 nm [2] to allow high permeability to water and small solutes out of the glomerulary capillary bed [2,3]. The diameter of albumin, the most abundant protein in plasma, is ~3.6 nm, but only a tiny fraction of this protein normally reaches Bowman’s space, suggesting that the size of the fenestrae does not substantially contribute to the permselectivity of the glomerular barrier. A high density of fibers in the fenestrae, possibly consisting of negatively charged proteoglycans, apparently influences the permselectivity of the capillary wall [2].

The glomerular basement membrane is composed of an intertwined network of extracellular matrix proteins consisting of collagen type IV, laminin, and nidogen/entactin, with attached proteoglycans such as agrin and perlecan with heparin sulfate chains, as well as glycoproteins. These chains contribute to the selective properties of the filtration barrier [4,5]. Although its role in renal permselectivity has been debated, the glomerular basement membrane is an important part of filtration barrier, as it restricts the flux of fluid. The thickness of basement membrane in the glomerulus (300–350 nm) is twice that of other vascular beds [6]. Abnormalities in the glomerular basement membrane give rise to several pathological conditions characterized by proteinuria and microscopic hematuria [7].

Podocytes on the urinary side of the glomerular basement membrane are terminally differentiated epithelial cells that participate in several glomerular functions, including maintenance of the filtration barrier, regulation of glomerular filtration, support of the capillary tuft, turnover of components of the glomerular basement membrane, production and secretion of vascular endothelial growth factor necessary for the integrity of glomerular endothelial cells, and immunological functions [810]. These cells are attached to the underlying glomerular basement membrane via integrins and dystroglycans [11,12]. They are connected to neighboring podocytes by highly specialized gap junctions called slit membranes with ~40 nm-diameter pore-like structures [13]. The glomerular basement membrane and the slit diaphragm constitute the primary barrier for filtration of blood into the urinary compartment, by virtue of their charge and physical characteristics [1416].

The mesangium is the central region of the glomerulus, comprised of specialized cells with surrounding extracellular matrix that supports the structure and helps to maintain patency of the glomerular capillary bed [17,18]. The only barrier to cross for circulating proteins to reach the mesangium is the endothelial fenestrae. The mesangial matrix consists of collagens, laminin, fibronectin, and proteoglycans with heparin sulfate and chondroitin sulfate chains [19,20]. In some renal diseases, immune complexes from the circulation characteristically attach to mesangial cells. The consequence is cellular activation and proliferation and secretion of cytokines, complement components, and extracellular matrix proteins [19,21]. Activated mesangial cells may also release several growth factors, cytokines, and reactive oxygen species that damage the glomerular basement membrane and podocytes, leading to proteinuria [2224].

Formation of urine

The kidneys receive about 20–25% of the cardiac output and filtration occurs in the glomerular capillary bed. Glomerular filtration rate (GFR) is the product of [net filtration pressure × hydraulic permeability × filtration area in the glomerular capillaries]. The net ultrafiltration pressure is the difference between the hydrostatic and the osmotic pressures across the capillary loop. In most persons, about 20% of the fluid portion of the blood crosses the filtration barrier to enter Bowman’s space. The cellular elements remain in the capillary lumen to re-enter the systemic circulation. This primary urine has a volume of about 180 liters per day (corresponding to a GFR of 125 ml/min) that contains about 1.5 kg sodium chloride. Proteins with a molecular weight less than 20 kDa easily cross the filtration barrier. As the molecular mass of a protein increases, the fraction that is filtered progressively decreases such that compounds of 60–70 kDa are largely retained in the capillary lumen. The electrical charge of the solutes also influences filtration; negatively charged proteins enter Bowman’s space in amounts far smaller than would be predicted by size criteria.

The downstream tubular portions of the nephron reclaim ~98–99% of the filtered salt and water, and the vast majority of the small proteins in the primary urine. The segments in the tubule vary in their roles in this process, differentially reabsorbing water and solutes [25,26]. More distal segments of the tubule fine-tune the excretion of water, urea, calcium, potassium, and other solutes through reclamation or secretory processes.

Genesis of proteinuria

In the final voided urine, the excreted protein does not normally exceed 150 mg per day, of which albumin accounts for about 20 mg. About half of the protein in the urine of normal individuals is derived from the tubules downstream from the glomerulus or from sources outside of the nephron.

Proteinuria due to glomerular injury

Proteins enter the urinary space through several physiological and pathophysiological mechanisms (Table 1; for further reading, see [27]). Proteins may exit the capillary circulation by crossing the three-layer filtration barrier comprised of the fenestrated endothelial cells, glomerular basement membrane and slit diaphragms of the podocytes. Small proteins (<20 kDa) are freely filtered but are readily reabsorbed downstream by proximal tubular cells. If the podocytes are injured with resultant loss of the organized structure of the actin-rich cytoskeleton [28], undergo changes in the slit-diaphragm proteins, or lose their negative charge on the cell surface, or if the composition and organization of the glomerular basement membrane is altered, they exhibit a characteristic change in appearance: effacement of their foot processes [10]. This alteration is a simplification of the inter-digitating foot processes due to retraction, widening and shortening of the processes of the podocytes. This change is energy-dependent and the result is a flattened elongated appearance of the podocytes and fewer slit diaphragms [10] (Figure 2). In that setting, substantial amounts of moderate-size proteins (e.g., 65-kDa albumin) may enter the primary urine [27]. In some renal diseases, even larger proteins (such as immunoglobulins) leak into the urinary space. The amount of protein excreted by patients with glomerular diseases spans a wide range, from 100 mg to ~20 g per day, depending on the specific disorder. The lower amount is within the normal range, while excretion of greater than 3 g/24h/1.73m2 often leads to nephrotic syndrome, manifested as edema, hypoproteinemia (especially hypoalbuminemia), hypercholesterolemia, and lipiduria.

Figure 2
Electron micrographs of glomerular capillary loops. (A) Glomerulus from a patient with nephrotic-range proteinuria. Black arrows indicate areas of effacement of the foot processes of the epithelial podocyte. Effacement is associated with a substantial ...
Table 1
Classification of proteinuria and main causes.

Injury to podocytes, accompanied by foot-process effacement, has been grouped into three classifications: congenital, hereditary and acquired [10]. An example of the first is development of maternal antibodies to fetal neutral endopeptidases that are absent in the mother. Hereditary causes often include genetically determined alterations in podocyte-specific proteins that are often components of the slit diaphragm or the cytoskeleton. Acquired injuries may be subdivided into immune causes (injury due to direct effects of immunoglobulin or immune complexes on the podocytes or indirect effects mediated by alterations in T cells) and non-immune causes (infection with HIV virus, or metabolic or local hypertension arising from diabetes-mediated damage in the mesangium) [10]. Some immune-complex-mediated renal diseases with the initial injury predominantly in the mesangium may damage podocytes through the local release of cytokines or oxidants [2935].

In a few instances, proteinuria occurs in the absence of effacement of the foot processes of the podocytes [36]. Clinical examples are preeclampsia of pregnancy [37], glomerulonephritis with severe endothelial injury, and some types of familial nephropathy with nephrotic syndrome [38].

Proteinuria due to renal tubular mechanisms

The renal tubules may account for proteinuria by three mechanisms. The first is the fact that excessive filtration may exceed the tubular capacity for reabsorption or degradation. This situation occurs most commonly with plasma cell dyscrasias such as multiple myeloma, amyloidosis, and lymphomas that are associated with monoclonal production of immunoglobulin light chains. These proteins are not only poorly absorbed by tubular cells, but also exert a toxic effect on these cells that leads to scarring and decreased renal clearance function [3032].

The second mechanism of tubular proteinuria arises from significant injury in the renal interstitium, the tissue surrounding the glomeruli and tubules that includes peritubular capillary and lymphatic networks (Figure 1). Damaged proximal tubular cells may shed brush-border proteins with loss of enzymes, ion channels and transporters, transmembrane glycoproteins and intracellular enzymes. Some proteins enter the urine as a consequence of sloughing of whole tubular epithelial cells [33,34]. This pattern of pathology is common even in diseases in which the inciting event starts in the glomeruli [39]. Inflammation is the most common process to induce interstitial damage and it proceeds in a highly regulated fashion [40,41]. In addition, leukocytes infiltrating the interstitium as a component of the inflammation secrete chemical mediators (e.g., cytokines or chemokines) that alter vascular permeability. These cells may also release other proteins (e.g., IgA) not normally detected in the urine. The effect is often augmentation of the interstitial injury and the outcome is either resolution with return of the histology and function to normal or scarring with fibrosis, tubular atrophy and loss of function [3941]. Increased interstitial volume due to fibrosis correlates with the degree of impairment of renal function and is a useful histological marker to assess clinical prognosis [40].

A third mechanism for tubular proteinuria is the excretion of exosomes [42]. Their origin may include all of the epithelial cells in the nephron. Whether markers associated with exosomes will be clinically useful in patients with renal disease is not clear, although a recent study of phosphoproteins of urinary exosomes showed absence of the sodium-potassium-chloride co-transporter 2 from urine samples of patients with a genetic renal disease, Bartter syndrome type I [43]. Furthermore, two studies indicated that exosomal proteins may serve as markers of acute kidney injury [44,45].

The quantity of proteins of a tubular source excreted by patients with injured tubules generally does not exceed 1,000 mg per day. As a means to distinguish tubular from glomerular sources of proteinuria, the amount of low-molecular-weight β2-microglobulin relative to albumin is measured [35]. A ratio substantially above the normal value of 0.1 mg/mg characterizes tubular proteinuria.

Excretion of proteins originating outside of the nephron

Excreted proteins may originate at locations outside of the kidney. Small- or middle-molecular-weight proteins entering the circulating blood from other organs may pass through the normal filtration barrier into the proximal tubules in quantities sufficient to escape total reclamation. These proteins may have been secreted into the plasma by any of a wide variety of cells, or be contained within exosomes. Furthermore, proteins may also enter the urine at points downstream from the nephron. These sources include the uroepithelium of the ureter or bladder (e.g., secretory IgA) and, in men, secretions from the prostate gland and vas deferens.

Measurement of proteinuria

The screening test for proteinuria is generally a dipstick urinalysis using a strip of dye-impregnated paper. However, this approach entails several important inherent limitations. Conventional dipsticks detect predominantly albumin in concentrations 20–300 mg/dL and, thus, may not detect concentrations of albumin commonly found in patients with microalbuminuria excreting 30–300 mg albumin per day, considering the usual daily volume of urine is 1–3 liters [27]. Even patients excreting increased amounts of other serum proteins may not test positive by a dipstick analysis that depends on the concentration of protein in the urine sample. A very dilute urine (e.g., specific gravity less than 1.004) may not register the abnormality. In addition, the dipstick is insensitive to immunoglobulins. Alternatively, an alkaline or concentrated urine sample, macroscopic hematuria (visible urinary bleeding) or the presence of some drugs (e.g., cephalosporins and iodinated radiocontrast), mucus, semen or white blood cells may cause a false-positive reading. Contaminants entering the urine during the voiding process, menstrual blood or vaginal secretions, may also lead to such a misleading result.

Dipstick proteinuria should be confirmed by a colorimetric or turbidometric assay for total protein. More precise determinations of proteinuria are derived from measurements in a 24-hour collection or a random “spot” sample to calculate the protein/creatinine ratio. About 85% of urinary creatinine is derived from the circulation as a result of filtration across the glomerular basement membrane, with about 15% originating from secretion by renal tubular cells. Thus, excretion of creatinine is used as a gauge of GFR in patients with reasonably well preserved clearance function. However, it is often difficult for individuals to collect a timed sample of urine correctly. Although the rate of protein excretion varies during the day, due to differences in posture, physical activity, intake of dietary protein and hemodynamic factors [46], several studies have found that the urinary protein/creatinine ratio in a spot urine sample closely correlated with the 24-hour excretion [4648]. Because of the excellent correlation between these two approaches and its less cumbersome collection technique, use of a random sample has gained increasing favor in the clinic (for details on other current laboratory tests for urinary protein analysis, please see [49]). The National Kidney Foundation of the United States has concluded that a random sample suffices for the quantitative measurement of proteinuria. A normal urinary protein/creatinine ratio is less than 0.1 g/g [50,51].

Proteinuria in patients with renal disease

Most physicians interpret the importance of proteinuria in the context of GFR. The most frequently used estimate of GFR in clinical practice is creatinine clearance. The amount of creatinine excreted per day depends on the muscle mass of the individual and, to some degree, on physical activity. These factors vary with age, race and body composition. GFR declines with age starting in the fourth decade, by as much as 8 mL/min/1.73m2/decade [52]. Use of creatinine clearance becomes increasingly problematic as damage to the nephron worsens and GFR declines because the amount of creatinine entering the urine as a result of tubular secretion is proportionally greater. Some investigators have favored measurement of another compound, cystatin C, as a better measure of GFR [53]. The use of iothalamate or inulin can overcome this problem, because both are freely filtered in the glomerulus and neither is secreted to a significant degree. However, use of either compound requires an intravenous infusion and, thus, this approach is not practical for clinical purposes. To minimize the complicating factors in the use of creatinine clearance to assess renal clearance function, the National Kidney Foundation of the United States has endorsed two equations that take age, sex, and ethnicity into account:

  1. Cockcroft-Gault creatinine clearance [54], mL/min:
    (140-age[years])×weight[kg]72×serumcreatinineconcentration[mg/dL]
    Above formula is for men; multiply by 0.85 to obtain the result for women
  2. Modification of Diet in Renal Disease study (MDRD) estimated GFR, abbreviated version [55], mL/min/1.73m2:
    • Estimated GFR = 186 × [serum creatinine concentration]−1.154 × [age]−0.203 × [0.742, if female] × [1.210, if black]
    • The four-variable MDRD calculation or use of an extended equation that includes two more clinical parameters, blood urea nitrogen (BUN) and serum albumin concentrations, can be done easily at the website http://newtech.kidney.org/professionals/kdoqi/gfr_calculator.cfm.

Both formulas entail some inaccuracies at the higher range of GFR and the current recommendation is to report a specific value for estimated GFR only if the result is less than 60 mL/min/1.73m2. Evidence of kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine, or by imaging studies. Chronic kidney disease is defined as either evidence of kidney damage or GFR <60mL/min/1.73m2.

Nearly all (99%) normal persons excrete less than 150 mg protein per day. The major exception to this criterion applies to normal pregnancy. Due to an increase in GFR that begins early in gestation (perhaps due to hormonally mediated vasodilatation) and continues through the third trimester, the upper limit for normal increases to 300 mg per day. Overt proteinuria, an amount that is easily detectable by routine screening methods, generally ranges 300 – 500 mg per day. To satisfy the standard for chronic kidney disease, overt proteinuria should be documented on several occasions over a three-month interval. Such a persistent abnormality must be distinguished from transient proteinuria that may be detected in the normal persons with short-term losses due to exercise or a febrile illness or in diabetic patients with poor glycemic control.

Overt proteinuria usually precedes decline in GFR, particularly in patients with diseases initially damaging the filtration barrier, and is generally asymptomatic. As the glomerular injury progresses, or in patients with diseases affecting the other components of the nephron, proteinuria may worsen due to scarring of the glomerular basement membrane or damage of the renal epithelial cells. For these patients, a spot urine protein/creatinine ratio measurement is at least as reliable as a 24-hour urinary protein collection in predicting progression of renal disease [48]. Patients whose inciting injury is confined to the tubular and interstitial compartments of the kidney (e.g., nephrotoxins or vascular insufficiency) often have proteinuria of a modest degree. Assays for particular peptides (e.g., β2-microglobulin and kidney injury molecule-1) are used to confirm the tubular source of the proteinuria and they have been proposed as biomarkers for acute kidney injury (for review, see [56]).

In an effort to detect glomerular renal injury at earlier stages, investigators have turned their attention to the excretion of albumin. Microalbuminuria (excretion of 30–300 mg albumin per day or per g creatinine) may indeed be more sensitive than overt proteinuria in this regard. For example, in patients with type 1 diabetes mellitus, microalbuminuria may occur in as few as five years after the onset of insulin dependency. Compared to normoalbuminuric patients, individuals with persistent microalbuminuria have a three- to four-fold greater risk to progress to overt proteinuria and loss of clearance function [57,58]. From another perspective, among microalbuminuric patients with type 1 diabetes mellitus, 20–45% progress to overt proteinuria over the next 10 years, 30–60% remain microalbuminuric, and the rest return to normoalbuminuria [59,60]. Some investigators contend that microalbuminuria is not the first clinical sign of renal disease in patients with type 1 diabetes mellitus, but this opinion remains controversial [60].

Clinically, proteinuria is classified as "selective" when albumin constitutes a substantial majority of the urinary protein or “nonselective” when the profile of the excreted protein reflects that of the proteins in the circulation. When the urinary protein losses exceed 3 g per day, the serum albumin concentration usually decreases due the liver’s inability to synthesize sufficient albumin to compensate for the urinary losses, and edema frequently develops. Proteinuria in most adults with glomerular disease is non-selective. In contrast, in patients with orthostatic proteinuria (manifests only while the individual is upright, and usually carries a benign prognosis), the pattern is highly selective [61]. Many clinical studies support the association of worsening proteinuria with progressive damage to the nephron and loss of clearance function [6264]. The simplest hypothesis for this observation is that increasingly severe proteinuria triggers a downstream inflammatory cascade around epithelial cells of the renal tubules, leading to interstitial injury, fibrosis, and tubular atrophy. Because albumin is an abundant polyanion in circulating blood and binds a variety of cytokines, chemokines, and lipid mediators [6569], it is plausible that in patients with glomerular proteinuria these small molecules initiate interstitial inflammation. Furthermore, glomerular injury may add activated mediators to the filtrate or alter the balance of cytokine inhibitors and activators, leading to a critical level of activated cytokines that damage downstream tubular epithelial cells. However, after uptake of albumin, epithelial cells lining the proximal tubules release an array of cytokines and chemokines that contribute to the inflammation in the interstitial compartment. As the inflammation heals, the resultant scarring can substantially decrease glomerular filtration. Indeed, some investigators have indicated that the degree of interstitial scarring is a better marker for prognosis than glomerular scarring in patients with some forms of glomerulonephritis [70]. Studies have shown that patients excreting substantial amounts of β2-microglobulin (proximal tubular source) and IgG or albumin (glomerular source) have an unfavorable clinical course [71,72]. High concentrations of IgG or albumin may damage the podocyte cytoskeleton [73].

Diagnosis of proteinuric renal disease

Although some patients with proteinuria due to structural abnormalities of the kidney (polycystic disease, congenital dysplasia, or reflux nephropathy) may be diagnosed by non-invasive imaging techniques such as magnetic resonance or ultrasound, the gold standard for most patients with proteinuria due to glomerulus-based disorders is the renal biopsy. Using a percutaneous approach, often during localization with real-time ultrasound, a small sample of renal tissue is removed with a cutting needle. Evaluation of the tissue includes light microscopy, immunofluorescence studies and electron microscopy, and the diagnostic yield is usually much better for glomerular diseases than for other types of renal disorders. Patients with glomerular disease (glomerulonephritis, termed an “inflammation” of the glomerulus) usually have morphological alterations in the glomeruli and clinically exhibit microscopic hematuria with varying degrees of proteinuria, generally more than 1 g per day (Table 1). For patients with glomerular renal diseases, the biopsy generally provides sufficient details to allow diagnosis and to address the approach for treatment. Patients with diseases for which therapy may include use of immunomodulatory drugs for years, such as lupus nephritis, renal vasculitis or IgA nephropathy, repetitive biopsy is frequently undertaken for monitoring the histological response and adjusting treatment. Serious complications of renal biopsy due to bleeding are not uncommon [74,75]. The procedure is more difficult in young children for whom conscious sedation is required.

Proteomic analysis of urine

As can be appreciated from the above discussion, urine contains a wide variety of compounds, ranging from small-molecular-mass molecules, such as metabolites, to peptides and polypeptides and finally to macromolecular complexes, such as exosomes [76,77]. Analysis of each of these different components requires specific approaches, and, consequently, specialized fields such as metabolomics, proteomics, and peptidomics have emerged. Each approach has contributed to discipline of urinary biomarker research. Although these fields differ, many common considerations apply, being dictated by general requirements of clinically-related studies [78]. In the sections below, we review some of these aspects, with emphasis on proteomics and peptidomics.

Technical aspects of proteomics and peptidomics

Before a sample of body fluid is analyzed in a clinical laboratory for specific biomarker(s) of a disease, several aspects of the methodology must be taken into account. First, collection and storage of the sample must be tested for reliability and, if necessary, optimized. While sampling renal tissue that is directly affected by the disease process would be ideal, this procedure is invasive and quite expensive and entails well-documented risk (as discussed in greater detail in the accompanying Viewpoint in this issue). Proteins/peptides may be shed or secreted into the local circulation. Unfortunately, collection of blood from young children can be a traumatic experience for the patient and parents. But even in older children and adults, sampling of blood has significant shortfalls. While blood is a rich source of proteins and peptides, potential biomarkers present in modest quantities may escape detection because of the difficulties encountered in the process of separating them during the preparation steps or analytical assays from more abundant material of about the same charge or size. Second, the handling and preparation of the sample should be kept to a minimum. A protocol that includes immediately freezing the sample, such as serum with its abundant enzymatic activity that may degrade the biomarker of interest, is a challenging requirement in a standard clinical setting. Third, a validated platform and, if possible and applicable, even an FDA-approved method of detection should be used and performed under reproducible conditions with appropriate controls. Fourth, the results should be reported in an easy-to-understand format with appropriate reference values. All of these facets assume that a specific biomarker or panel of biomarkers was identified and characterized with suitable methods for detection. For analysis of urinary proteomic biomarkers of renal diseases, most researchers have indicated that the second-void sample of the day provides the most reproducible results [79,80]. Use of the second-void sample shortens exposure of compounds to proteases in the urine and potentially lessens the risk for reduction in the concentration or alteration of the composition of a potential biomarker. However, some prefer a first-void sample if the search is for markers of bladder cancer [81,82] due to the potentially greater amount excreted. Several recent publications summarize the experience and suggestions for sample handling and provide a detailed discussion of other considerations relevant to urinary proteome analysis in clinical settings [78,83,84]. Urine samples can be stored frozen, ideally in aliquots to prevent repeated freeze-thaw cycles [84]. The temperature should be −20°C or lower. If the sample is to be stored for more than five years, a temperature of −80°C is preferable [84]. Preparation of urine specimens for analysis is entirely dependent on the particular markers being assayed and on the methodology used. In principle, proteomic techniques usually require two-step protocols, separation and detection, that are frequently coupled with a specific method for sample preparation. The optimal clinical assay should require minimal handling of the sample, to reduce cost and risk of possible artifacts.

Proteomic techniques rely most frequently on gel or column separation, followed by an on-line or off-line detection method, such as mass spectrometry (MS) or immunodetection. Table 2 compiles the commonly used proteomic separation and detection techniques for analysis of urinary biomarkers. As noted, each technique has its advantages and disadvantages that must be considered for the clinical application. In addition, factors such as turn-around time, expense of equipment, training of laboratory personnel, reproducibility, calibration and standardization, and central laboratory vs. portable instrument should be considered. For biomarker identification, parameters such as reproducibility of sample preparation and sample analysis must be considered as well as statistical analysis applied for identification of relevant biomarkers [76,78].

Table 2
Examples of proteomic separation and detection techniques for analysis of biomarkers.

Validation of the identification of the peaks shown by MS is vital in establishing confidence in the process that defined a biomarker of interest. It is also important to ascertain additional data that may be practical for expanding the clinical usefulness of the biomarker. More detailed information about the composition of the biomarker may clarify the pathophysiology of the disease process and lead to better treatment. Furthermore, such precise particulars may guide development of an independent, rapid, highly accurate and less expensive assay, such as one using an isotope-labeled standard or antibody. One approach to characterize a peptide biomarker is to establish its sequence.

Protein sequencing takes advantage of MS-based dissociation of the target ion. Commonly, these ions are fragmented by collision-induced dissociation (CID) with atoms of an inert gas [85,86]. After dissociation, the masses of the produced fragments are recorded (MS/MS scan) and, by subtracting consecutive signals, adjacent residues are determined. Repetition of this process can determine the amino acid sequence of the entire peptide. CID has some important inherent limitations: (1) fragmentation often fails with peptides with a high content of Pro, Arg, and/or Lys, (2) post-translational modifications (PTMs) complicate interpretation of spectra, and (3) longer peptides (≥15–18 amino acids) yield poor information. However, with use of an ion trap MS, CID can produce several spectra per second for many types of peptides and, thus, can sequence thousands of peptides in a day. To enhance the effectiveness of CID for larger peptides and proteins, additional steps prior to MS analysis are included, such as proteolytic digests (using site-specific proteases such as trypsin or chymotrypsin) sometimes combined with removal of PTMs (e.g., deglycosylation of glycoproteins).

In 1998, a new method for peptide/protein ion fragmentation was introduced, electron capture dissociation (ECD), using a Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer [87]. In contrast to CID, ECD does not preferentially cleave PTMs from modified peptide ions and more randomly cleaves the backbone bonds of large peptides and even whole protein ions. This feature enables, in many instances, direct characterization of whole proteins (top-down approach) [88106].

As the ECD fragmentation is limited to FT-ICR MS instruments, investigators have sought to develop a similarly effective fragmentation technique using a more commonly available instrument. These efforts produced a new ion dissociation method, electron transfer dissociation (ETD), that can be performed using a bench-top mass spectrometer with an ion trap [85,86,107110]. This approach uses negatively charged ions to deliver the electron. With an appropriate electron-transfer reagent, the transferred electron induces fragmentation of the peptide backbone. Both ECD and ETD fragment cations of peptides and proteins in a relatively sequence-independent fashion, can be used for identification of PTMs, and can be performed on a chromatographic time-scale.

Application of FT-ICR MS has permitted analysis of various PTMs, including the aberrancies in the O-glycosylation of IgA1 hinge-region glycopeptides [111,112] that play a central role in the pathogenesis of IgA nephropathy, as discussed below. FT-ICR MS enables heterogeneity profiling of glycopeptides as well as detailed sequence-specific studies due to the availability of MS/MS techniques with FT-ICR MS (fragmentation using CID, ECD, ETD, and infrared-multiphoton dissociation, IRMPD). These approaches facilitate identification of the sites of attachment of glycans on IgA1 and are applicable to other types of PTMs on other proteins in various organisms [85,99,102,113119].

Clinical examples

It is not necessary that patients exhibit clinical proteinuria or even have renal disease before urinary proteomics may be considered as a potentially useful tool in diagnosis. As has been shown for patients with coronary disease [120] or urological cancers [121,122], urinary proteomics can detect biomarkers of disease in the absence of abnormal proteinuria.

Several centers have addressed the question of whether urinary proteomics is helpful in the identification of the type of renal disease or in the assessment of the prognosis. While several challenges must be addressed before for urinary proteomics can be adapted for the clinic (please see the accompanying Viewpoint in this issue) preliminary findings suggest that this approach has the potential to be developed into diagnostic assays that would be less expensive and safer than the current methods. One example with substantial clinical impact is patients with IgA nephropathy, the most common form of glomerulonephritis worldwide [123]. This disease is a leading cause of end-stage renal failure [124] and apparently arises due to mesangial deposition of circulating immune complexes [125,126] containing galactose-deficient IgA1 [127,128]. While the serum level of this aberrant immunoglobulin [129] and the urinary excretion of IgA-containing immune complexes [130,131] are elevated in patients with IgA nephropathy [129], renal biopsy is still necessary for an accepted diagnosis [76,78,130143]. A recent study used CE-MS to identify a panel of polypeptide biomarkers that distinguished patients with IgA nephropathy from those with other renal disorders with a 90% sensitivity and 90% specificity [144]. The origin of the fragments distinctive for IgA nephropathy remains unknown, but unique proteases in inflamed glomeruli or in the urine may generate disease-specific polypeptides [145]. Similar evidence for apparently disease-specific urinary biomarkers has been reported for patients with other common renal diseases, including membranous glomerulonephritis, focal segmental glomerulosclerosis, systemic lupus erythematosus, minimal-change disease and diabetic nephropathy [135,146], using SELDI-TOF MS [78,132,135137,141,144149]. Otu et al. found a urinary 12-peak protein signature in Pima Indians with type 2 diabetes mellitus and normoalbuminuria that predicted development of diabetic nephropathy 10 years later [150]. If validated, these findings will lead to a more focused approach to treatment, and hopefully a reduction in the prevalence of diabetic nephropathy. For patients with other types of renal disorders, the diagnosis requires careful refinement before proceeding with investigations of the urinary proteome. For example, a cohort of patients with the clinical diagnosis (without a renal biopsy) of hypertensive renal disease may have a spectrum of renal pathology that differs greatly from nephrosclerosis due to primary hypertension. Indeed, in a study of patients presenting for transplantation for renal failure attributed hypertensive renal disease, many patients had clinical evidence of proteinuria suggestive of undiagnosed glomerular disease [151]. Embarking on a search for disease-specific urinary biomarker (pattern) using proteomic methods in this setting would be futile, or worse, misleading.

Urinary proteomics may nevertheless prove to be valuable for the clinic because the currently applied diagnostic methods are expensive and entail risks for morbidity, and diagnosis in the earliest stages of renal injury provides an opportunity to therapeutically intervene for the best outcome. It is necessary to validate findings in large prospective multi-center studies that permit assessment of the specificity and sensitivities of the different approaches. Irrespective of the technology, certain rules and approaches should be followed to maximize the clinical impact of each study [78]. Along these lines, a publicly accessible database of the urinary peptidome was published in 2008, providing a new tool for studies focused on urinary biomarkers [135,152157].

Summary

Renal diseases affect a substantial portion of the world’s population and account for a significant fraction of the costs of health care. Afflicted individuals manifest a wide spectrum of clinical and laboratory features. For patients with the largest subset of renal diseases, i.e. glomerular disorders, renal biopsy is the current standard for diagnosis, and for directing and monitoring therapy. Unfortunately, this test is invasive and expensive. These aspects frequently limit the applicability of the biopsy procedure, often denying patients an opportunity for early diagnosis and treatment before irreversible renal injury has developed. Recent advances in urinary proteomic analyses have the potential to significantly enhance the care of patients with renal disease, as well as other disorders, and to alleviate some of the financial burden on the health care system. To fully realize the potential of these emerging techniques, it is vital that clinicians and basic scientists understand the processes by which proteins are excreted in the urine. By building on this foundation, investigators will more likely minimize the pitfalls that often slow the pace of progress in medical research.

Acknowledgements

The authors thank Mr. David Fisher for his artistic help with Figure 1. BAJ, SH, and JN were supported in part by NIH grants DK078244, DK080301, DK071802, DK077279, DK061525, and DK064400, General Clinical Research Center of the University of Alabama at Birmingham (M01 RR00032), and by CCTS grant 1UL1RR025777-01.

Abbreviations

GFR
glomerular filtration rate
IgA
immunoglobulin A
MDRD
modified diet in renal disease
MRM
multiple reaction monitoring
SID
stable isotope dilution

Footnotes

Conflict of interest statement

The authors do not have any financial/commercial conflicts of interest to declare.

References

1. Briggs JP, Kriz W, Schnermann JB. In: Primer on Kidney Disease. Greenberg A, editor. Philadelphia: Elsevier Saunders; 2005. pp. 2–19.
2. Rostgaard J, Qvortrup K. Sieve plugs in fenestrae of glomerular capillaries--site of the filtration barrier? Cells Tissues Organs. 2002;170:132–138. [PubMed]
3. Deen WM, Lazzara MJ, Myers BD. Structural determinants of glomerular permeability. Am. J. Physiol. Renal Physiol. 2001;281:F579–F596. [PubMed]
4. Hassell JR, Robey PG, Barrach HJ, Wilczek J, et al. Isolation of a heparan sulfate-containing proteoglycan from basement membrane. Proc. Natl. Acad. Sci. USA. 1980;77:4494–4498. [PubMed]
5. Kanwar YS, Linker A, Farquhar MG. Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J. Cell. Biol. 1980;86:688–693. [PMC free article] [PubMed]
6. Bonsib SM. In: Heptinstall's Pathology of the Kidney. Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 1–70.
7. Barker DF, Hostikka SL, Zhou J, Chow LT, et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science. 1990;248:1224–1227. [PubMed]
8. Hauser PV, Collino F, Bussolati B, Camussi G. Nephrin and endothelial injury. Curr. Opin. Nephrol. Hypertens. 2009;18:3–8. [PubMed]
9. Mundel P, Kriz W. Structure and function of podocytes: an update. Anat. Embryol. (Berl) 1995;192:385–397. [PubMed]
10. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006;69:2131–2147. [PubMed]
11. Sever S, Altintas MM, Nankoe SR, Moller CC, et al. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J. Clin. Invest. 2007;117:2095–2104. [PMC free article] [PubMed]
12. Ronco P. Proteinuria: is it all in the foot? J. Clin. Invest. 2007;117:2079–2082. [PMC free article] [PubMed]
13. Wartiovaara J, Ofverstedt LG, Khoshnoodi J, Zhang J, et al. Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. J. Clin. Invest. 2004;114:1475–1483. [PMC free article] [PubMed]
14. Asanuma K, Yanagida-Asanuma E, Takagi M, Kodama F, et al. The role of podocytes in proteinuria. Nephrology (Carlton) 2007;12 Suppl 3:S15–S20. [PubMed]
15. Kriz W. Progressive renal failure--inability of podocytes to replicate and the consequences for development of glomerulosclerosis. Nephrol. Dial. Transplant. 1996;11:1738–1742. [PubMed]
16. Yu D, Petermann A, Kunter U, Rong S, et al. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J. Am. Soc. Nephrol. 2005;16:1733–1741. [PubMed]
17. Michael AF. The glomerular mesangium. Contrib. Nephrol. 1984;40:7–16. [PubMed]
18. Inkyo-Hayasaka K, Sakai T, Kobayashi N, Shirato I, et al. Three-dimensional analysis of the whole mesangium in the rat. Kidney Int. 1996;50:672–683. [PubMed]
19. Mene P, Simonson MS, Dunn MJ. Physiology of the mesangial cell. Physiol. Rev. 1989;69:1347–1424. [PubMed]
20. Ohyama K, Seyer JM, Raghow R, Kang AH. Extracellular matrix phenotype of rat mesangial cells in culture. Biosynthesis of collagen types I, III, IV, and V and a low molecular weight collagenous component and their regulation by dexamethasone. J. Lab. Clin. Med. 1990;116:219–227. [PubMed]
21. Schlondorff D. The glomerular mesangial cell: an expanding role for a specialized pericyte. FASEB J. 1987;1:272–281. [PubMed]
22. Abboud HE, Poptic E, DiCorleto P. Production of platelet-derived growth factorlike protein by rat mesangial cells in culture. J. Clin. Invest. 1987;80:675–683. [PMC free article] [PubMed]
23. Aron DC, Rosenzweig JL, Abboud HE. Synthesis and binding of insulin-like growth factor I by human glomerular mesangial cells. J. Clin. Endocrinol. Metab. 1989;68:585–591. [PubMed]
24. Zoja C, Wang JM, Bettoni S, Sironi M, et al. Interleukin-1 β and tumor necrosis factor-α induce gene expression and production of leukocyte chemotactic factors, colonystimulating factors, and interleukin-6 in human mesangial cells. Am. J. Pathol. 1991;138:991–1003. [PubMed]
25. Evan AP, Gattone VH, 2nd, Connors BA. Ultrastructural features of the rabbit proximal tubule. Arch. Histol. Cytol. 1992;55 Suppl:139–145. [PubMed]
26. Brenner BM, Falchuk KH, Keimowitz RI, Berliner RW. The relationship between peritubular capillary protein concentration and fluid reabsorption by the renal proximal tubule. J. Clin. Invest. 1969;48:1519–1531. [PMC free article] [PubMed]
27. Glassock RJ. In: Primer on Kidney Disease. Greenberg A, editor. Philadelphia: Elsevier Saunders; 2005. pp. 36–46.
28. Hsu HH, Hoffmann S, Endlich N, Velic A, et al. Mechanisms of angiotensin II signaling on cytoskeleton of podocytes. J. Mol. Med. 2008;86:1379–1394. [PubMed]
29. Lai KN, Leung JC, Chan LY, Saleem MA, et al. Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol. Dial. Transplant. 2009;24:62–72. [PubMed]
30. Lee YJ, Han HJ. Albumin-stimulated DNA synthesis is mediated by Ca2+/PKC as well as EGF receptor-dependent p44/42 MAPK and NF-kappaB signal pathways in renal proximal tubule cells. Am. J. Physiol. Renal Physiol. 2008;294:F534–F541. [PubMed]
31. Batuman V. Proximal tubular injury in myeloma. Contrib. Nephrol. 2007;153:87–104. [PubMed]
32. Pote A, Zwizinski C, Simon EE, Meleg-Smith S, et al. Cytotoxicity of myeloma light chains in cultured human kidney proximal tubule cells. Am. J. Kidney Dis. 2000;36:735–744. [PubMed]
33. Oliver J, Macdowell M, Lee YC. Cellular mechanisms of protein metabolism in the nephron. I. The structural aspects of proteinuria; tubular absorption, droplet formation, and the disposal of proteins. J. Exp. Med. 1954;99:589–604. [PMC free article] [PubMed]
34. Zoja C, Benigni A, Remuzzi G. Cellular responses to protein overload: key event in renal disease progression. Curr. Opin. Nephrol. Hypertens. 2004;13:31–37. [PubMed]
35. Schardijn GH, Statius van Eps LW. Beta 2-microglobulin: its significance in the evaluation of renal function. Kidney Int. 1987;32:635–641. [PubMed]
36. Kalluri R. Proteinuria with and without renal glomerular podocyte effacement. J. Am. Soc. Nephrol. 2006;17:2383–2389. [PubMed]
37. Pirani CL, Pollak VE, Lannigan R, Folli G. The Renal Glomerular Lesions of Pre-Eclampsia: Electron Microscopic Studies. Am. J. Obstet. Gynecol. 1963;87:1047–1070. [PubMed]
38. Branten AJ, van den Born J, Jansen JL, Assmann KJ, et al. Familial nephropathy differing from minimal change nephropathy and focal glomerulosclerosis. Kidney Int. 2001;59:693–701. [PubMed]
39. Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure. Intern. Med. 2004;43:9–17. [PubMed]
40. Strutz F, Muller GA. Interstitial pathomechanisms underlying progressive tubulointerstitial damage. Kidney Blood Press. Res. 1999;22:71–80. [PubMed]
41. Palmer BF. The renal tubule in the progression of chronic renal failure. J. Investig. Med. 1997;45:346–361. [PubMed]
42. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc. Natl. Acad. Sci. USA. 2004;101:13368–13373. [PubMed]
43. Gonzales PA, Pisitkun T, Hoffert JD, Tchapyjnikov D, et al. Large-scale proteomics and phosphoproteomics of urinary exosomes. J. Am. Soc. Nephrol. 2009;20:363–379. [PubMed]
44. Zhou H, Cheruvanky A, Hu X, Matsumoto T, et al. Urinary exosomal transcription factors, a new class of biomarkers for renal disease. Kidney Int. 2008;74:613–621. [PMC free article] [PubMed]
45. Zhou H, Pisitkun T, Aponte A, Yuen PS, et al. Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int. 2006;70:1847–1857. [PMC free article] [PubMed]
46. Rodby RA, Rohde RD, Sharon Z, Pohl MA, et al. The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. Am. J. Kidney Dis. 1995;26:904–909. [PubMed]
47. Schwab SJ, Christensen RL, Dougherty K, Klahr S. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch. Intern. Med. 1987;147:943–944. [PubMed]
48. Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ. 1998;316:504–509. [PMC free article] [PubMed]
49. Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ. 2007;177:361–368. [PMC free article] [PubMed]
50. Hutchison AS, O'Reilly DS, MacCuish AC. Albumin excretion rate, albumin concentration, and albumin/creatinine ratio compared for screening diabetics for slight albuminuria. Clin. Chem. 1988;34:2019–2021. [PubMed]
51. Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J. Am. Soc. Nephrol. 2002;13:1034–1039. [PubMed]
52. Hoang K, Tan JC, Derby G, Blouch KL, et al. Determinants of glomerular hypofiltration in aging humans. Kidney Int. 2003;64:1417–1424. [PubMed]
53. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am. J. Kidney Dis. 2002;40:221–226. [PubMed]
54. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41. [PubMed]
55. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002;39:S1–S266. [PubMed]
56. Han WK, Waikar SS, Johnson A, Betensky RA, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int. 2008;73:863–869. [PMC free article] [PubMed]
57. Mann JF, Yi QL, Gerstein HC. Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney Int. 2004:S59–S62. [PubMed]
58. de Jong PE, Gansevoort RT. Prevention of chronic kidney disease: the next step forward! Nephrology (Carlton) 2006;11:240–244. [PubMed]
59. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes. 2000;49:1399–1408. [PubMed]
60. Caramori M, Mauer M. Primer on Kidney Disease. Philadelphia: Elsevier Saunders; 2005. pp. 241–248.
61. Wingo CS, Clapp WL. Proteinuria: potential causes and approach to evaluation. Am. J. Med. Sci. 2000;320:188–194. [PubMed]
62. Yamagata K, Iseki K, Nitta K, Imai H, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin. Exp. Nephrol. 2008;12:1–8. [PubMed]
63. Palmer BF. Proteinuria as a therapeutic target in patients with chronic kidney disease. Am. J. Nephrol. 2007;27:287–293. [PubMed]
64. Jafar TH, Stark PC, Schmid CH, Landa M, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60:1131–1140. [PubMed]
65. Zoja C, Morigi M, Figliuzzi M, Bruzzi I, et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am. J. Kidney Dis. 1995;26:934–941. [PubMed]
66. Wang Y, Chen J, Chen L, Tay YC, et al. Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J. Am. Soc. Nephrol. 1997;8:1537–1545. [PubMed]
67. Zoja C, Donadelli R, Colleoni S, Figliuzzi M, et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-κB activation. Kidney Int. 1998;53:1608–1615. [PubMed]
68. Tang S, Leung JC, Abe K, Chan KW, et al. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J. Clin. Invest. 2003;111:515–527. [PMC free article] [PubMed]
69. Nakajima H, Takenaka M, Kaimori JY, Hamano T, et al. Activation of the signal transducer and activator of transcription signaling pathway in renal proximal tubular cells by albumin. J. Am. Soc. Nephrol. 2004;15:276–285. [PubMed]
70. Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J. Nephrol. 2005;18:503–512. [PubMed]
71. D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int. 2003;63:809–825. [PubMed]
72. Branten AJ, Wetzels JF. Influence of albumin infusion on the urinary excretion of beta2-microglobulin in patients with proteinuria. Nephron. 1999;81:329–333. [PubMed]
73. Morigi M, Buelli S, Angioletti S, Zanchi C, et al. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am. J. Pathol. 2005;166:1309–1320. [PubMed]
74. Madaio MP. Renal biopsy. Kidney Int. 1990;38:529–543. [PubMed]
75. Parrish AE. Complications of percutaneous renal biopsy: a review of 37 years' experience. Clin. Nephrol. 1992;38:135–141. [PubMed]
76. Fliser D, Novak J, Thongboonkerd V, Argilés À, et al. Advances in urinary proteome analysis and biomarker discovery. J. Am. Soc. Nephrol. 2007;18:1057–1071. [PubMed]
77. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J. Am. Soc. Nephrol. 2004;15:1677–1689. [PubMed]
78. Mischak H, Apweiler R, Banks RE, Conaway M, et al. Clinical Proteomics: a need to define the field and to begin to set adequate standards. Proteomics-Clin. Appl. 2007;1:148–156. [PubMed]
79. Goodsaid F, Bandow J, Mischak H. REPORT - Grand Rounds in Proteomics at the FDA (White Oak, Silver Spring, MD, USA, April 3, 2007) Proteomics Clin. Appl. 2007;1:1526–1531. [PubMed]
80. HKUPP. 2nd HKUPP Workshop"Towards Standards for Urine Proteomics"; November 1, 2006; San Francisco, CA, USA: 2006.
81. Theodorescu D. Molecular pathogenesis of urothelial bladder cancer. Histol. Histopathol. 2003;18:259–274. [PubMed]
82. Schiffer E, Mischak H, Theodorescu D, Vlahou A. Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform. World J. Urol. 2008;26:67–74. [PubMed]
83. Lee RS, Monigatti F, Briscoe AC, Waldon Z, et al. Optimizing sample handling for urinary proteomics. J. Proteome Res. 2008 [PubMed]
84. Thongboonkerd V. Practical points in urinary proteomics. J. Proteome Res. 2007;6:3881–3890. [PubMed]
85. Coon JJ, Syka JE, Shabanowitz J, Hunt DF. Tandem mass spectrometry for peptide and protein sequence analysis. Biotechniques. 2005;38:519–523. [PubMed]
86. Coon JJ, Ueberheide B, Syka JE, Dryhurst DD, et al. Protein identification using sequential ion/ion reactions and tandem mass spectrometry. Proc. Natl. Acad. Sci. USA. 2005;102:9463–9468. [PubMed]
87. Zubarev RA, Kelleher NL, McLafferty FW. Electron capture dissociation of multiply charged protein cations. A nonergodic process. J. Am. Chem. Soc. 1998;120:3265–3266.
88. Farrugia JM, O'Hair RAJ, Reid GE. Do all b(2) ions have oxazolone structures? Multistage mass spectrometry and ab initio studies on protonated N-acyl amino acid methyl ester model systems. Int. J. Mass Spectrom. 2001;210:71–87.
89. Valaskovic GA, Kelleher NL, McLafferty FW. Attomole protein characterization by capillary electrophoresis-mass spectrometry. Science. 1996;273:1199–1202. [PubMed]
90. Reid GE, Shang H, Hogan JM, Lee GU, et al. Gas-phase concentration, purification, and identification of whole proteins from complex mixtures. J. Am. Chem. Soc. 2002;124:7353–7362. [PubMed]
91. Stephenson JL, McLuckey SA, Reid GE, Wells JM, et al. Ion/ion chemistry as a top-down approach for protein analysis. Curr. Opin. Biotechnol. 2002;13:57–64. [PubMed]
92. Davey CA, Sargent DF, Luger K, Maeder AW, et al. Solvent mediated interactions in the structure of the nucleosome core particle at 1.9 A resolution. J. Mol. Biol. 2002;319:1097–1113. [PubMed]
93. Sze SK, Ge Y, Oh H, McLafferty FW. Top-down mass spectrometry of a 29-kDa protein for characterization of any posttranslational modification to within one residue. Proc. Natl. Acad. Sci. USA. 2002;99:1774–1779. [PubMed]
94. VerBerkmoes NC, Bundy JL, Hauser L, Asano KG, et al. Integrating "top-down" and "bottom-up" mass spectrometric approaches for proteomic analysis of Shewanella oneidensis. J. Proteome Res. 2002;1:239–252. [PubMed]
95. Hogan JM, Pitteri SJ, McLuckey SA. Phosphorylation site identification via ion trap tandem mass spectrometry of whole protein and peptide ions: bovine alpha-crystallin A chain. Anal. Chem. 2003;75:6509–6516. [PubMed]
96. He M, McLuckey SA. Charge permutation reactions in tandem mass spectrometry. J. Mass Spectrom. 2004;39:1231–1259.
97. Ge Y, Lawhorn BG, ElNaggar M, Sze SK, et al. Detection of four oxidation sites in viral prolyl-4-hydroxylase by top-down mass spectrometry. Protein Sci. 2003;12:2320–2326. [PubMed]
98. Ge Y, Lawhorn BG, ElNaggar M, Strauss E, et al. Top down characterization of larger proteins (45 kDa) by electron capture dissociation mass spectrometry. J. Am. Chem. Soc. 2002;124:672–678. [PubMed]
99. Zabrouskov V, Giacomelli L, van Wijk KJ, McLafferty FW. A new approach for plant proteomics: characterization of chloroplast proteins of Arabidopsis thaliana by top-down mass spectrometry. Mol. Cell. Proteomics. 2003;2:1253–1260. [PubMed]
100. Amunugama R, Hogan JM, Newton KA, McLuckey SA. Whole protein dissociation in a quadrupole ion trap: identification of an a priori unknown modified protein. Anal. Chem. 2004;76:720–727. [PubMed]
101. Newton KA, Pitteri SJ, Laskowski M, Jr, McLuckey SA. Effects of single amino acid substitution on the collision-induced dissociation of intact protein ions: Turkey ovomucoid third domain. J. Proteome Res. 2004;3:1033–1041. [PMC free article] [PubMed]
102. Forbes AJ, Patrie SM, Taylor GK, Kim YB, et al. Targeted analysis and discovery of posttranslational modifications in proteins from methanogenic archaea by top-down MS. Proc. Natl. Acad. Sci. USA. 2004;101:2678–2683. [PubMed]
103. Kelleher NL. Top-down proteomics. Anal. Chem. 2004;76:197A–203A. [PubMed]
104. Pesavento JJ, Kim YB, Taylor GK, Kelleher NL. Shotgun annotation of histone modifications: a new approach for streamlined characterization of proteins by top down mass spectrometry. J. Am. Chem. Soc. 2004;126:3386–3387. [PMC free article] [PubMed]
105. Geer LY, Markey SP, Kowalak JA, Wagner L, et al. Open mass spectrometry search algorithm. J. Proteome Res. 2004;3:958–964. [PubMed]
106. Oh HB, Lin C, Hwang HY, Zhai H, et al. Infrared photodissociation spectroscopy of electrosprayed ions in a Fourier transform mass spectrometer. J. Am. Chem. Soc. 2005;127:4076–4083. [PubMed]
107. Coon JJ, Shabanowitz J, Hunt DF, Syka JE. Electron transfer dissociation of peptide anions. J. Am. Soc. Mass Spectrom. 2005;16:880–882. [PubMed]
108. Chi A, Coon JJ, Syka JEP, Bai D, et al. Efficient, large-scale phosphoproteome analysis with electron transfer dissociation mass spectrometry. Proceedings of the 53rd ASMS Conference; San Antonio, TX. 2005. p. 2005.
109. Syka JE, Coon JJ, Schroeder MJ, Shabanowitz J, et al. Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc. Natl. Acad. Sci. USA. 2004;101:9528–9533. [PubMed]
110. Coon JJ, Syka JEP, Schwartz JC, Shabanowitz J, et al. Anion dependence in the partitioning between proton and electron transfer in ion/ion reactions. Int. J. Mass Spectrom. 2004;236:33–42.
111. Renfrow MB, MacKay CL, Chalmers MJ, Julian BA, et al. Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: Implications for IgA nephropathy. Anal. Bioanal. Chem. 2007;389:1397–1407. [PubMed]
112. Renfrow MB, Cooper HJ, Tomana M, Kulhavy R, et al. Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation Fourier transform-ion cyclotron resonance mass spectrometry. J. Biol. Chem. 2005;280:19136–19145. [PubMed]
113. Chalmers MJ, Hakansson K, Johnson R, Smith R, et al. Protein kinase A phosphorylation characterized by tandem Fourier transform ion cyclotron resonance mass spectrometry. Proteomics. 2004;4:970–981. [PubMed]
114. Håkansson K, Cooper HJ, Emmett MR, Costello CE, et al. Electron capture dissociation and infrared multiphoton dissociation MS/MS of an N-glycosylated tryptic peptic to yield complementary sequence information. Anal. Chem. 2001;73:4530–4536. [PubMed]
115. Håkansson K, Chalmers MJ, Quinn JP, McFarland MA, et al. Combined electron capture and infrared multiphoton dissociation for multistage MS/MS in a Fourier transform ion cyclotron resonance mass spectrometer. Anal. Chem. 2003;75:3256–3262. [PubMed]
116. Kelleher RL, Zubarev RA, Bush K, Furie B, et al. Localization of labile posttranslational modifications by electron capture dissociation: The case of gamma-carboxyglutamic acid. Anal. Chem. 1999;71:4250–4253. [PubMed]
117. Marshall AG, Hendrickson CL, Jackson GS. Fourier transform ion cyclotron resonance mass spectrometry: A primer. Mass Spectrom. Rev. 1998;17:1–35. [PubMed]
118. Mirgorodskaya E, Roepstorff P, Zubarev RA. Localization of O-glycosylation sites in peptides by electron capture dissociation in a Fourier transform mass spectrometer. Anal. Chem. 1999;71:4431–4436. [PubMed]
119. Mormann M, Paulsen H, Peter-Katalinic J. Electron capture dissociation of O-glycosylated peptides: radical site-induced fragmentation of glycosidic bonds. Eur. J. Mass Spectrom. 2005;11:497–511. [PubMed]
120. Zimmerli LU, Schiffer E, Zurbig P, Good DM, et al. Urinary proteomic biomarkers in coronary artery disease. Mol. Cell. Proteomics. 2008;7:290–298. [PubMed]
121. Rasmussen HH, Orntoft TF, Wolf H, Celis JE. Towards a comprehensive database of proteins from the urine of patients with bladder cancer. J. Urol. 1996;155:2113–2119. [PubMed]
122. Sarto C, Deon C, Doro G, Hochstrasser DF, et al. Contribution of proteomics to the molecular analysis of renal cell carcinoma with an emphasis on manganese superoxide dismutase. Proteomics. 2001;1:1288–1294. [PubMed]
123. Julian BA, Waldo FB, Rifai A, Mestecky J. IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? Am. J. Med. 1988;84:129–132. [PubMed]
124. Wyatt RJ, Julian BA, Bhathena DB, Mitchell BL, et al. IgA nephropathy: presentation, clinical course, and prognosis in children and adults. Am. J. Kidney Dis. 1984;4:192–200. [PubMed]
125. Berger J, Hinglais N. Les depots intercapillaires d'IgA-IgG (Intercapillary deposits of IgA-IgG) J. Urol. Nephrol. 1968;74:694–695. [PubMed]
126. Jennette JC. The immunohistology of IgA nephropathy. Am. J. Kidney Dis. 1988;12:348–352. [PubMed]
127. Hiki Y, Odani H, Takahashi M, Yasuda Y, et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int. 2001;59:1077–1085. [PubMed]
128. Allen AC, Bailey EM, Brenchley PEC, Buck KS, et al. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: Observations in three patients. Kidney Int. 2001;60:969–973. [PubMed]
129. Moldoveanu Z, Wyatt RJ, Lee J, Tomana M, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 2007;71:1148–1154. [PubMed]
130. Matousovic K, Novak J, Tomana M, Kulhavy R, et al. IgA1-containing immune complexes in the urine of IgA nephropathy patients. Nephrol. Dial. Transplant. 2006;21:2478–2484. [PubMed]
131. Julian BA, Wittke S, Novak J, Good DM, et al. Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis. 2007;28:4469–4483. [PubMed]
132. Haubitz M, Wittke S, Weissinger EM, Walden M, et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 2005;67:2313–2320. [PubMed]
133. Haubitz M, Mischak H, Julian BA, Novak J. Urinary protein patterns as a diagnostic tool in patients with IgA nephropathy. European Renal Disease - Touch Briefings 2008. In Press.
134. Good DM, Zürbig P, Bauer HW, Behrens G, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol. Cell. Proteomics. 2008 Submitted. [PMC free article] [PubMed]
135. Coon JJ, Zürbig P, Dakna M, Dominiczak AF, et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics-Clin. Appl. 2008;2:964–973. [PMC free article] [PubMed]
136. Park MR, Wang EH, Jin DC, Cha JH, et al. Establishment of a 2-D human urinary proteomic map in IgA nephropathy. Proteomics. 2006;6:1066–1076. [PubMed]
137. Rocchetti MT, Centra M, Papale M, Bortone G, et al. Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics. 2008;8:206–216. [PubMed]
138. Novak J, Wittke S, Haubitz M, Walden M, et al. Urinary protein analyses reveal patterns and biomarkers specific for IgA nephropathy (IgAN) J. Am. Soc. Nephrol. 2005;16:155.
139. Mischak H, Julian BA, Novak J. High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine. Proteomics-Clin. Appl. 2007;1:792–804. [PMC free article] [PubMed]
140. Julian BA, Wyatt RJ, Matousovic K, Moldoveanu Z, et al. IgA nephropathy: a clinical overview. Contrib. Nephrol. 2007;157:19–26. [PubMed]
141. Schiffer E, Mischak H, Novak J. High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with mass spectrometry. Proteomics. 2006;6:5615–5627. [PubMed]
142. Galla JH, Spotswood MF, Harrison LA, Mestecky J. Urinary IgA in IgA nephropathy and Henoch-Schoenlein purpura. J. Clin. Immunol. 1985;5:298–306. [PubMed]
143. Halling SFE, Söderberg MP, Berg UB. Henoch-Schönlein nephritis: clinical findings related to renal function and morphology. Pediatr. Nephrol. 2005;20:46–51. [PubMed]
144. Julian BA, Wittke S, Novak J, Zürbig P, et al. Urinary polypeptide biomarkers of IgA-associated renal diseases. J. Am. Soc. Nephrol. 2007;18 782A.
145. Candiano G, Musante L, Bruschi M, Petretto A, et al. Repetitive fragmentation products of albumin and α1-antitrypsin in glomerular diseases associated with nephrotic syndrome. J. Am. Soc. Nephrol. 2006;17:3139–3148. [PubMed]
146. Rossing K, Mischak H, Dakna M, Zurbig P, et al. Urinary proteomics in diabetes and CKD. J. Am. Soc. Nephrol. 2008;19:1283–1290. [PubMed]
147. Neuhoff N, Kaiser T, Wittke S, Krebs R, et al. Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun. Mass Spectrom. 2004;18:149–156. [PubMed]
148. Mischak H, Kaiser T, Walden M, Hillmann M, et al. Proteomic analysis for the assessment of diabetic renal damage in humans. Clin. Sci. (Lond) 2004;107:485–495. [PubMed]
149. Kolch W, Neususs C, Pelzing M, Mischak H. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom. Rev. 2005;24:959–977. [PubMed]
150. Otu HH, Can H, Spentzos D, Nelson RG, et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care. 2007;30:638–643. [PubMed]
151. Schlessinger SD, Tankersley MR, Curtis JJ. Clinical documentation of end-stage renal disease due to hypertension. Am. J. Kidney Dis. 1994;23:655–660. [PubMed]
152. Wolfe RA, Ashby VB, Milford EL, Ojo AO, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med. 1999;341:1725–1730. [PubMed]
153. Ivanyi B. A primer on recurrent and de novo glomerulonephritis in renal allografts. Nat. Clin. Prac. Nephrol. 2008;4:446–457. [PubMed]
154. Clarke W, Silverman BC, Zhang Z, Chan DW, et al. Characterization of renal allograft rejection by urinary proteomic analysis. Ann. Surg. 2003;237:660–664. discussion 664–665. [PubMed]
155. Wittke S, Haubitz M, Walden M, Rohde F, et al. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am. J. Transplant. 2005;5:2479–2488. [PubMed]
156. Schaub S, Rush D, Wilkins J, Gibson IW, et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 2004;15:219–227. [PubMed]
157. Schaub S, Wilkins JA, Nickerson P. Proteomics and renal transplantation: searching for novel biomarkers and therapeutic targets. Contrib. Nephrol. 2008;160:65–75. [PubMed]
158. Trocme C, Marotte H, Baillet A, Pallot-Prades B, et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for Infliximab response in rheumatoid arthritis. Ann. Rheum. Dis. 2008 In Press, PMID: 18664547. [PMC free article] [PubMed]
159. Zhang X, Jin M, Wu H, Nadasdy T, et al. Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int. 2008;74:799–807. [PMC free article] [PubMed]
160. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science. 2006;312:212–217. [PubMed]
161. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006;24:971–983. [PubMed]